The FDA today approved the first non-opioid treatment designed to help manage the symptoms of opioid withdrawal in adults.
The drug, Lucemyra, isn’t a treatment for opioid use disorder, the agency noted. Instead, it is meant to be used as part of a broader plan to help adults manage their symptoms when they stop using opioids.
This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.
ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.
Take a look at our full agenda.
Use the code "TRACKS" to save 15% on the cost of registration.